Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44(V6)/anti-gallium chelate antibodies

Journal of Nuclear Medicine

Volumn 39, Issue 10, 1998, Pages 1769-1776

  Klivényi, Gabor ^b   Schuhmacher, Jochen ^a   Patzelt, Erik ^b   Hauser, Harald ^b   Matys, Ronald ^b   Moock, Marion ^b   Regiert, Thomas ^b   Maier Borst, Wolfgang ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NONE

Author keywords

Bispecific antibodies; Gallium 68; Immunoscintigraphy; PET; Pretargeting

Indexed keywords

BISPECIFIC ANTIBODY; GALLIUM 68; HERMES ANTIGEN; IODINE 125; MONOCLONAL ANTIBODY;

ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CANCER DIAGNOSIS; COLON CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC IMAGING; IMAGE ANALYSIS; IMMUNOSCINTIGRAPHY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD44; CHELATING AGENTS; COLONIC NEOPLASMS; EDETIC ACID; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNODETECTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031666670     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Chatal JF, Peltier P, Bardies M et al. Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy? Eur J Nucl Med 1992;19:205-213.
2. Larson SM, Divgi C, Scott A, Daghighian F, Macapinlac H, Welt S. Current status of radioimmunodetection. Nucl Med Biol 1994;21:721-729.
3. Bischof-Delaloye A, Delaloye B. Radiolabeled monoclonal antibodies in tumor imaging and therapy: out of fashion? Eur J Nucl Med 1995;22:571-580.
4. Larson SM. Improving the balance between treatment and diagnosis: a role for radioimmunodetection. Cancer Res 1995;55(suppl):5756s-5758s.
5. Goodwin DA. Tumor pretargeting: almost the bottom line. J Nucl Med 1995;36:876-879.
6. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-4347.
7. 111In labeled monoclonal antibody B6.2 by the rat liver. Cancer Res 1990;50(suppl):852s-856s.
8. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(suppl):814s-819s.
9. Juweid M, Neuman R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992;52:5144-5153.
10. 111In labeled bifunctional haptens. J Nucl Med 1988;29:226-234.
11. 111 In labeled bivalent haptens to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990;50:3445-3452.
12. Paganelli G, Magnani F, Zito E, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-5966.
13. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993;34:1662-1671.
14. 64Cu-labeled monoclonal antibodies. J Nucl Med 1995;36:1818-1824.
15. Schuhmacher J, Klivényi G, Matys R, et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res 1995;55:115-123.
16. Zöller M, Schuhmacher J, Reed J, Maier-Borst W, Matzku S. Establishment and characterization of monoclonal antibodies against an octahedral galliumchelate suitable for immunoscintigraphy with PET. J Nucl Med 1992;33:1366-1372.
17. v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 1996;43:245-253.
18. Günthert U. CD44 in malignant disorders. Curr Top Microbiol Immunol 1996;213: 271-285.
19. Rall CJN, Rustgi AK. CD44 isoform expression in primary and metastatic pancreatic adenocarcinomas. Cancer Res 1995;55:1831-1835.
20. Günthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993;184:47-63.
21. Parham P, Androlewicz MJ, Brodsky FM, Holnus NJ, Ways JP. Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J Immunol Methods 1982;53:133-173.
22. 2 fragments from mouse IgG of various subclasses. J Immunol Methods 1983;56:235-243.
23. Fogh J, Trempe G. New human tumor cell lines. In: Fogh J, ed. Human tumor cells in vitro. New York: Plenum Press; 1975:115-159.
24. Hofmann M, Rudy W, Zöller M et al. CD44 splice variants confer metastatic behaviour in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-5297.
25. 68Ga in dilute HCl. Int J Appl Radiat Isot 1981;32:31-36.
26. Lindmo T, Boven E, Cuttita F, Fedorko J, Bunn PA. Determination of the immuno-reactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
27. Badger CC, Krohn KA, Bernstein ID. In vitro measurement of avidity of radioiodonated antibodies. Nucl Med Biol 1987;14:605-610.
28. Doll J, Brix G, Bellemann ME, et al. Improvement of spatial resolution in PET by implementing scanner characteristics in iterative image reconstruction algorithms. In: Richter J, ed. Medizinische physik 1995. Jahrestagung der deutschen gesellschaft für medizinische physik. Frankfurt: Linea Plus Druck; 1995:322-323.
29. Stewart M. Antigenerkennung. In: Roitt IM, Brostoff J, Male DK, eds. Immunologie, 2nd ed. Stuttgart: Georg Thieme Verlag; 1991:79-89 (German translation, Harabacz I).
30. Goodwin DA, Meares CF, McTigue M, et al. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med 1992;33:2006-2013.
31. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
32. Stauder R, Eisterer W, Thaler J, Günthert U. CD 44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995;85:2885-2889.
33. 6-containing CD44 proteins. Lancet 1994;344:1470-1472.
34. v6 on survival in colorectal carcinoma. Lancet 1995;345:327-328.
35. Kaufmann M, Heider KH, Sinn HP, Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-619.
36. Friedrichs K, Franke F, Lisboa BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55: 5424-5433.